Monday, July 9, 2018

KemPharm's stock soars after ADHD drug trial meets primary endpoints - MarketWatch


Baseball Daily Digest

KemPharm's stock soars after ADHD drug trial meets primary endpoints
MarketWatch
Shares of KemPharm Inc. KMPH, +4.65% shot up 13% in premarket trade Monday after the specialty pharmaceutical company said a trial of its treatment of ADHD in patients between the ages of 6 and 12 (KP415) met primary and secondary efficacy ...
KemPharm (KMPH) Says KP415.E01 Efficacy and Safety Trial in Children With ADHD Met Primary EndpointStreetInsider.com
KemPharm, Inc. (KMPH)'s Stock Is Sell After FormingSC Daily (press release)

all 5 news articles »

No comments:

Post a Comment